• Notice of Clarification on Eligible Organizations for RFA-CA-17-057 Limited Competition: NCI National Clinical Trials Network – Network Group Statistics and Data Management Centers (U01)  
  (NOT-CA-18-018)  
  National Cancer Institute

• Notice of Correction to RFA-CA-135 “Pre-Cancer Atlas (PCA) Research Centers (U2C)”  
  (NOT-CA-18-022)  
  National Cancer Institute

• Notice of a Pre-Application Webinar for RFA-CA-18-016, “Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability (U01)”  
  (NOT-CA-18-016)  
  National Cancer Institute

• Notice of NHLBI Participation in PA-17-225 “Advancing the Science of Geriatric Palliative Care (R01)”  
  (NOT-HL-17-558)  
  National Heart, Lung, and Blood Institute

• Notice of Extension of the Release Date for NOT-LM-17-006 “Request for Information (RFI): Next-Generation Data Science Challenges in Health and Biomedicine”  
  (NOT-LM-18-001)  
  National Library of Medicine

• Notice of Change in Application Due dates for PAR-17-001 “Emerging Global Leader Award (K43)”  
  (NOT-TW-18-001)  
  National Cancer Institute

• 2018 NIH Regional Seminar on Program Funding & Grants Administration – Early Registration Rates Available Now  
  (NOT-OD-18-013)  
  National Institutes of Health

• NIH will Make the Project Outcomes Section of all Interim and Final RPPRs Submitted on or After October 1, 2017 Available via the NIH RePORTER  
  (NOT-OD-18-103)  
  National Institutes of Health

• Notice of Clarification on Eligible Organizations for RFA-CA-17-057 Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10)  
  (NOT-CA-18-018)  
  National Cancer Institute

• Notice of Correction to RFA-CA-17-035 "Pre-Cancer Atlas (PCA) Research Centers (U2C)"  
  (NOT-CA-18-022)  
  National Cancer Institute

• Notice of Expiration of PAR-15-289 “The Pancreatic Cancer Detection Consortium (U01)”  
  (NOT-CA-18-029)  
  National Cancer Institute

REQUEST FOR APPLICATIONS

• TITLE: The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)  
  (RFA-CA-18-001)  
  SPONSOR: National Cancer Institute  
  Synopsis: The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers. Application Receipt Date(s): February 21, 2018

• TITLE: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21- Clinical Trials Not Allowed)  
  (RFA-CA-18-002)  
  SPONSOR: National Cancer Institute  
  Synopsis: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Receipt Date(s): February 28, 2018; May 29, 2018; September 28, 2018

• TITLE: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33- Clinical Trial Not Allowed)
SPONSOR: National Cancer Institute

Synopsis: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer.

Receipt Date(s): February 28, 2018; May 29, 2018; September 28, 2018

- TITLE: Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21- Clinical Trial Not Allowed)
  (RFA-CA-18-004)
  SPONSOR: National Cancer Institute
  Synopsis: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.
  Receipt Date(s): February 28, 2018; May 29, 2018; September 28, 2018

- TITLE: Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)
  (RFA-OD-18-001)
  SPONSOR: National Cancer Institute
  U.S. Food and Drug Administration, Center for Tobacco Products
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  Office of Disease Prevention
  Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to support New Investigators in the biomedical, behavioral, and social sciences who are in the early stages of establishing independent careers in tobacco regulatory research. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Applicants are encouraged to conduct projects that ultimately have potential to inform regulations on tobacco product manufacturing, distribution, and marketing.
  Receipt Date(s): Multiple dates, see announcement

- TITLE: Tobacco Regulatory Science (R01 Clinical Trial Optional)
  (RFA-OD-18-002)
  SPONSOR: National Cancer Institute
  U.S. Food and Drug Administration, Center for Tobacco Products
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  Office of Disease Prevention
  Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).
  Receipt Date(s): Multiple dates, see announcement

- TITLE: Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trials Optional)
  (RFA-CA-18-006)
  SPONSOR: National Cancer Institute
  Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called “competing revisions”) from currently funded NCI R01 research projects proposing to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.
  Receipt Date(s): Multiple dates, see announcement
**TITLE:** Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trials Optional)  
**SPONSOR:** National Cancer Institute  
**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects proposing to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.  
**Receipt Date(s):** Multiple dates, see announcement

**TITLE:** Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional)  
**SPONSOR:** National Cancer Institute  
**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U54 Resource-Related Research Projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.  
**Receipt Date(s):** Multiple dates, see announcement

**TITLE:** Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trials Optional)  
**SPONSOR:** National Cancer Institute  
**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications to incorporate a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program from currently funded NCI P50 specialized centers to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.  
**Receipt Date(s):** Multiple dates, see announcement

**PROGRAM ANNOUNCEMENTS**

**TITLE:** End of Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)  
**SPONSOR:** National Cancer Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Nursing Research, Office of Research on Women’s Health  
**Synopsis:** The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 – 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers. The objective is to support targeted clinical studies aimed at: 1) increasing this knowledge base, 2) the development of AYA-appropriate measurement tools and, 3) the design, testing, and evaluation of AYA-specific EOLPC models of care, and interventions that positively impact health-related quality of life for AYA with serious illness and their families/caregivers  
**Application Receipt/Submission Date(s):** Multiple dates, see announcement

**TITLE:** Innovative Questions in Symptom Science and Genomics (R01 Clinical Trial Optional)  
**SPONSOR:** National Institute of Nursing Research  
**Application Receipt/Submission Date(s):** Multiple dates, see announcement
• **TITLE:** Mechanisms, Models, Measurement, and Management in Pain Research (R01 Clinical Trial Optional) *(PA-18-141)*  
  **SPONSOR:** National Cancer Institute  
  National Center for Complementary and Integrative Health  
  National Institute on Aging  
  National Institute on Drug Abuse  
  National Institute of Dental and Craniofacial Research  
  National Institute of Diabetes and Digestive Kidney Diseases  
  National Institute on Minority Health and Health Disparities  
  National Institute of Neurological Disorders and Stroke  
  Application Receipt/Submission Date(s): Multiple dates, see announcement

• **TITLE:** Health Promotion Among Racial and Ethnic Minority Males *(PA-18-144)*  
  **SPONSOR:** National Institute of Nursing Research  
  National Institute of Diabetes and Digestive and Kidney Diseases  
  Application Receipt/Submission Date(s): Standard dates apply

• **TITLE:** Palliative Care Needs of Individuals with Advanced Rare Diseases and Their Family Caregivers (R01 Clinical Trial Optional) *(PA-18-149)*  
  **SPONSOR:** National Cancer Institute  
  National Institute of Nursing Research  
  **Synopsis:** This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.  
  Application Receipt/Submission Date(s): Multiple dates, see announcement

• **TITLE:** Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional) *(PAR-18-008)*  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.  
  Application Receipt/Submission Date(s): Standard dates apply

• **TITLE:** Early Phase Clinical Trials in Imaging and Image-Guide Interventions (R01 Clinical Trial Required) *(PAR-18-011)*  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies.  
  Application Receipt Date(s): Multiple dates, see announcement

• **TITLE:** Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional) *(PA-18-104)*  
  **SPONSOR:** National Cancer Institute  
  National Institute of Diabetes and Kidney Diseases  
  Eunice Kennedy Shriver National Institute of Child Health and Human Development  
  Office of Dietary Supplements  
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children. Exploratory epidemiological research with a goal of informing translational/clinical research will also be supported within this program.  
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE:** Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) *(PA-18-286)*  
  **SPONSOR:** National Cancer Institute  
  National Institute of Arthritis and Musculoskeletal and Skin Disease  
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute of Neurological Disorders and Stroke

**Synopsis:** The purpose of this FOA is to encourage submission of Exploratory/Developmental Bioengineering Research Grants (EBRG) applications which establish the feasibility of technologies, techniques or methods that: 1) explore a new multidisciplinary approach to a biomedical challenge; 2) are high-risk but have high impact; and 3) develop data that may lead to significant future research. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.

**Application Receipt Date(s):** Standard dates apply

- **TITLE:** Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)
  (PAR-18-018)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies.
  **Application Receipt Date(s):** Standard dates apply

- **TITLE:** NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
  (PAR-18-020)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies—including the use of new clinically-relevant models and imaging technologies—which could lead to first-in-human clinical trials.
  **Application Receipt Date(s):** Standard dates apply

- **TITLE:** Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional)
  (PA-18-084)
  **SPONSOR:** National Institute on Drug Abuse
  National Cancer Institute
  **Synopsis:** The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange.
  **Application Receipt Date(s):** Standard dates apply

- **TITLE:** Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R33 Clinical Trial Optional)
  (PAR-18-085)
  **SPONSOR:** National Cancer Institute
  National Institute on Drug Abuse
  National Institute on Alcohol Abuse and Alcoholism
  **Synopsis:** The purpose of this FOA is to provide support for applications that focus on data replication and the scalability of novel, targeted addiction treatments. Consistent with an experimental therapeutics approach, studies that would fall under the R33 (Phase II) would include studies with theory-derived targets (based on putative mechanisms of ATOD) and clearly defined hypotheses about how the proposed treatment directed at changing the target relates to clinical outcomes.
  **Application Receipt Date(s):** Standard dates apply

- **TITLE:** Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54)
  (PAR-18-361)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity population and underrepresented students (ISUPSSs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a stronger national
cancer program and address challenges in cancer and cancer disparities research, education and outreach, as well as their impact on underserved populations.

Application Receipt Date(s): Standard dates apply

- **TITLE:** NCI Mentored Research Scientist Development Award to Promote Diversity (K01) (PAR-18-365)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor.
  Application Receipt Date(s): Standard dates apply

- **TITLE:** Population Health Interventions: Integrating Individual and Group Level Evidence (R01) Clinical Trials Not Allowed (PA-18-356)
  **SPONSOR:** Office of Behavioral and Social Science Research
  National Cancer Institute
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  **Synopsis:** To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.
  Application Receipt Date(s): Standard dates apply

- **TITLE:** Population Health Interventions: Integrating Individual and Group Level Evidence (R01) Clinical Trial Optional (PA-18-385)
  **SPONSOR:** Office of Behavioral and Social Science Research
  National Cancer Institute
  National Institute of Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  **Synopsis:** To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.
  Application Receipt Date(s): Standard dates apply

- **TITLE:** NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional) (PAR-18-021)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Methodology and Measurement in the Behavioral and Social Sciences (R01) Clinical Trials Optional (PAR-18-352)
  **SPONSOR:** National Cancer Institute
  Office of Behavioral and Social Science Research
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Deafness and Other Communication Disorders
  Office of Disease Prevention
  Office of Research on Women’s Health
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to invite qualified researchers to submit grant applications aimed at improving and developing methodology in the behavioral and social sciences through innovations in research design, measurement, data collection and data analysis techniques.
  Application Receipt Date(s): Standard dates apply

- **TITLE:** NCI Transition Career Development Award to Promote Diversity (K22- No Clinical Trials) (PAR-18-366)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist
postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.

Application Receipt Date(s): Standard dates apply

- **TITLE:** Education and Health: New Frontiers (R01)- Clinical Trial Optional (PAR-18-387)
  **SPONSOR:** National Cancer Institute
  Office of Behavioral and Social Science Research
  National Institute on Aging
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  
  **Synopsis:** The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship.
  Application Receipt Date(s): Standard dates apply

- **TITLE:** Tobacco Use and HIV in Low and Middle Income Countries (R21 Clinical Trial Optional) (PAR-18-022)
  **SPONSOR:** National Institute on Drug Abuse
  National Cancer Institute
  
  **Synopsis:** The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Predicting Behavioral Responses to Population-Level Cancer Control Strategies (PAR-18-024)
  **SPONSOR:** National Cancer Institute
  
  **Synopsis:** The goal of this funding opportunity announcement (FOA) is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors. We seek to encourage collaborations among scientists with expertise in health policy research and implementation, as well as investigators in scientific disciplines that have not traditionally conducted cancer or policy research, such as: psychological science (e.g., social, developmental); affective and cognitive neuroscience; judgment and decision-making; consumer behavior and marketing; organizational behavior; sociology, cultural anthropology; behavioral economics; linguistics; and political science.
  Application Receipt Date(s): Standard dates apply

- **TITLE:** Building Evidence: Effective Palliative/End of Life Care Interventions (R01 Clinical Trial Optional) (PAR-18-173)
  **SPONSOR:** National Institute of Nursing Research
  
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional) (PAR-18-222)
  **SPONSOR:** National Cancer Institute
  National Institute on Drug Abuse
  National Institute on Alcohol Abuse and Alcoholism
  
  **Synopsis:** As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA, NIAAA, and NCI join to issue this FOA. The purpose of this FOA is to support the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services.
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional) (PAR-18-246)
  **SPONSOR:** National Cancer Institute
  
  **Synopsis:** This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3 Clinical Trial Optional)
SPONSOR: National Cancer Institute

Synopsis: This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials.

Application Receipt Date(s): Multiple dates, see announcement

• TITLE: Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01, Clinical Trial Optional) (PA-18-465)

SPONSOR: National Cancer Institute
National Institute on Drug Abuse
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Neurological Disorders and Stroke

Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

Application Receipt Date(s): Standard dates apply

• TITLE: NIH Research Project Grant (Parent R01 Clinical Trial Optional) (PA-18-484)

SPONSOR: National Cancer Institute

Synopsis: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept clinical trials.

Application Receipt Date(s): Multiple dates, see announcement

• TITLE: The NCI Transition Career Development Award (K22 Independent Clinical Trial Required) (PAR-18-466)

SPONSOR: National Cancer Institute

Synopsis: This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.

Application Receipt Date(s): Standard dates apply

• TITLE: The NCI Transition Career Development Award (K22 – Independent Clinical Trial Not Allowed) (PAR-18-467)

SPONSOR: National Cancer Institute

Synopsis: This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.

Application Receipt Date(s): Standard dates apply

• TITLE: Cancer Research Education Grants Program- Courses for Skills Development (R25) (PAR-18-477)

SPONSOR: National Cancer Institute

Synopsis: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Application Receipt Date(s): Standard dates apply

• TITLE: Cancer Research Education Grants Program- Research Experiences (R25) (PAR-18-478)

SPONSOR: National Cancer Institute

Synopsis: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer,
rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients, in accordance with the overall mission of the NCI. Application Receipt Date(s): Standard dates apply

**OTHER FUNDING OPPORTUNITIES**
(Sponsors in bold are NIH Peer Reviewed Organizations)

- **TITLE:** Clinical Investigator Award  
  [http://www.surgonc.org/foundation/clinical-investigator-awards](http://www.surgonc.org/foundation/clinical-investigator-awards)  
  **SPONSOR:** Society of Surgical Oncology (SSO)

- **TITLE:** NRC Research Associateship Programs  
  [http://sites.nationalacademies.org/PGA/RAP/index.htm?utm_source=RAP+Mailing+List&utm_campaign=b7e8e28839-NRC+RAP+Dec+4+email+campaign&utm_medium=email&utm_term=0_ff8fa39297-b7e8e28839-129099353](http://sites.nationalacademies.org/PGA/RAP/index.htm?utm_source=RAP+Mailing+List&utm_campaign=b7e8e28839-NRC+RAP+Dec+4+email+campaign&utm_medium=email&utm_term=0_ff8fa39297-b7e8e28839-129099353)  
  **SPONSOR:** The National Academies of Sciences, Engineering, and Medicine

- **TITLE:** IASLC Lung Cancer Fellowship and Young Investigators Awards  
  [https://www.iaslc.org/fellowship](https://www.iaslc.org/fellowship)  
  **SPONSOR:** International Association for the Study of Lung Cancer (IASLC)

- **TITLE:** Sojourns Award Program: Sojourns Scholar Leadership Program  
  **SPONSOR:** Cambia Health Foundation

- **TITLE:** Travel Grants- Women in Cancer Research Scholar Awards  
  [http://www.aacr.org/Meetings/Pages/Travel%20Grants/wicr-scholar-awards___36A82A.aspx#.Wi7c70qnEdV](http://www.aacr.org/Meetings/Pages/Travel%20Grants/wicr-scholar-awards___36A82A.aspx#.Wi7c70qnEdV)  
  **SPONSOR:** American Association for Cancer Research (AACR)

- **TITLE:** Neuroendocrine Tumor Research Foundation – AACR Grant  
  [http://www.aacr.org/Funding/Pages/Funding-Detail.aspx?ItemID=33#.Wi7dP0qnEdV](http://www.aacr.org/Funding/Pages/Funding-Detail.aspx?ItemID=33#.Wi7dP0qnEdV)  
  **SPONSOR:** American Association for Cancer Research (AACR)